{"schema_version":"alpha-company-profile-public-v2","slug":"adc-therapeutics-sa","canonical_url":"https://registry.alpha.ac/companies/adc-therapeutics-sa","published_on":"2026-10-17T04:46:43.578776+00:00","last_reviewed_on":"2026-10-17T04:46:43.578776+00:00","identity":{"legal_name":"ADC Therapeutics SA","display_name":"ADC Therapeutics SA","headline":"ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors.","description":"ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors.","ten_second_view":"This Company Profile publishes only Alpha's canonical identity and evidence-backed public leadership records. Unavailable fields are not inferred.","legal_form":"Not publicly asserted","incorporation":"Not publicly asserted","headquarters":"US","headquarters_address":{"locality":"Not publicly asserted","region":null,"country":"US"},"operating_presence":["US"],"website":"","cik":"0001771910","logo":"https://cdn.brandfetch.io/ticker/adct/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","logo_source":"brandfetch","profile_mark":{"src":"https://cdn.brandfetch.io/ticker/adct/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","alt":"ADC Therapeutics SA logo","width":256,"height":256,"source":"brandfetch"}},"entity_status":{"ownership_type":"unknown","listing_status":"listed","label":"Public listing published","explanation":"The canonical public record includes at least one active security listing.","source_id":"alpha-canonical-company-record","reviewed_on":"2026-10-17T04:46:43.578776+00:00"},"security_listings":[{"ticker":"ADCT","exchange":"NYSE","exchange_display":"NYSE","mic":"XNYS","currency":"Unavailable","security_type":"equity","listing_status":"active","is_primary":true,"source_id":"alpha-canonical-company-record"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market data is not published in this Company Profile."},"profile_tags":["Canonical identity","Public leadership"],"trust_summary":"Canonical identity published; broader company intelligence is not asserted.","facts":[{"label":"Legal name","value":"ADC Therapeutics SA","source_id":"alpha-canonical-company-record"},{"label":"Country","value":"US","source_id":"alpha-canonical-company-record"},{"label":"Sector","value":"Healthcare","source_id":"alpha-canonical-company-record"},{"label":"Industry","value":"Biotechnology","source_id":"alpha-canonical-company-record"}],"operating_model":{"eyebrow":"Operating record","title":"Published operating structure","units":[]},"governance":{"summary":"Only current, confirmed leadership roles with public evidence are included in the canonical projection.","boundary":"Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","disclosures":[]},"alpha_opinion":{"status":"Not published","label":"No Alpha opinion published","explanation":"This identity record is not an Alpha rating, score, or investment opinion."},"report":{"status":"Not published","label":"No governed report published","explanation":"No governed company report is attached to this profile.","href":null},"actions":[],"related_records":[],"evidence":[{"id":"alpha-canonical-company-record","label":"Alpha canonical company public projection","href":"/api/public/companies/adc-therapeutics-sa","source_type":"canonical_identity","supports":["Company identity","Published leadership","Entity status boundary"],"status":"published","reviewed_on":"2026-10-17T04:46:43.578776+00:00"}],"permissions":[{"label":"Public retrieval","allowed":true},{"label":"Agent retrieval","allowed":true},{"label":"Redistribution","allowed":false},{"label":"Model training","allowed":false},{"label":"Relationship pathfinding","allowed":false},{"label":"Direct contact","allowed":false}],"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"financials":{"kind":"financials","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"ownership":{"kind":"ownership","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented. 13F and N-PX are not beneficial ownership and are never projected here.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"trust":{"schema_version":"alpha-profile-trust-v1","verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":30,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"aggregation":{"schema_version":"alpha-claim-aggregation-v1","published_claim_count":30,"under_review_claim_count":1,"owner_supplied_claim_count":0,"evidence_record_count":3,"distinct_source_count":2,"conflicts":[],"conflict_count":0,"headline_conflict_count":0,"internal_review_conflict_count":0,"contradiction_types":[],"headline_conflict_types":[],"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":30,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"coverage":{"schema_version":"alpha-coverage-metric-v1","published_claims":30,"corroborated_claims":0,"sources":3,"distinct_sources":2,"role_claims":0,"last_reviewed_at":"2026-10-17T04:46:43.578776+00:00","observed_at":"2026-10-17T04:46:43.578776+00:00","freshness_days":0}},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"}},"projection":{"schema_version":"alpha-profile-projection-v5","entity":{"kind":"company","slug":"adc-therapeutics-sa","canonical_url":"https://registry.alpha.ac/companies/adc-therapeutics-sa"},"publication":{"published_at":"2026-10-17T04:46:43.578776+00:00","last_reviewed_at":"2026-10-17T04:46:43.578776+00:00","as_of":"2026-10-17T04:46:43.578776+00:00"},"representations":{"html":{"href":"https://registry.alpha.ac/companies/adc-therapeutics-sa","media_type":"text/html"},"json":{"href":"https://registry.alpha.ac/api/public/companies/adc-therapeutics-sa","media_type":"application/json"},"markdown":{"href":"https://registry.alpha.ac/companies/adc-therapeutics-sa.md","media_type":"text/markdown"},"structured_data":{"embedded":true,"media_type":"application/ld+json"},"share_image":null},"permissions":{"public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false}},"canonical_profile":{"schema_version":"alpha-company-profile-public-v1","slug":"adc-therapeutics-sa","canonical_url":"https://registry.alpha.ac/companies/adc-therapeutics-sa","as_of":"2026-10-17T04:46:43.578776+00:00","last_reviewed_at":"2026-10-17T04:46:43.578776+00:00","identity":{"legal_name":"ADC Therapeutics SA","display_name":"ADC Therapeutics SA","description":"ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients ","jurisdiction":null,"country":"US","sector":"Healthcare","industry":"Biotechnology","website":null,"website_provenance":null,"logo_url":null,"logo_media":null,"status":"active","cik":"0001771910","entity_subtype":null,"legal_entity_status":null},"security_listings":[{"mic":"XNYS","ticker":"ADCT","currency":null,"exchange":"NYSE","sort_key":0,"valid_to":null,"confidence":0.95,"is_primary":true,"listing_id":"131e6655-b2e7-4e92-a13d-cb53edf467d9","source_url":"https://www.sec.gov/files/company_tickers_exchange.json","valid_from":null,"observed_at":"2026-07-11T00:28:32+00:00","source_name":"sec_company_tickers_exchange","source_tier":1,"exchange_name":"New York Stock Exchange","security_type":"equity","listing_status":"active","last_checked_at":"2026-09-02T01:48:40.989053+00:00"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market observations are unpublished. Listing identity remains available from the governed source set."},"index_memberships":[],"index_membership_history":[],"index_membership_contract":{"schema_version":"alpha-index-membership-public-v1","as_of_date":"2026-10-17","tracked_universe_complete":false,"permissions":{"public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false},"limitations":["Only source-backed memberships with an explicit public redistribution basis are returned.","Absence from Alpha tracked indices does not establish absence from every market index.","Provider announcements and effective membership are represented as distinct states.","Alpha AI 100 is not published as a current public index membership."]},"leadership":{"board":[{"person_slug":"ameet-mallik","display_name":"Ameet Mallik","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2022-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"jean-pierre-bizzari","display_name":"Jean-Pierre Bizzari","role_category":"director","title":"Director","committee":"Nominating and Governance · Chair","is_board_chair":false,"is_independent":true,"start_date":"2022-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"jose-pepe-carmona","display_name":"Jose Pepe Carmona","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"mohamed-zaki","display_name":"Mohamed Zaki","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"peter-hug","display_name":"Peter Hug","role_category":"director","title":"Director","committee":"Compensation · Chair; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2019-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"peter-j-graham","display_name":"Peter J. Graham","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":null,"end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"robert-azelby","display_name":"Robert Azelby","role_category":"director","title":"Director","committee":"Audit; Compensation","is_board_chair":false,"is_independent":true,"start_date":"2023-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"ron-squarer","display_name":"Ron Squarer","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2020-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"timothy-coughlin","display_name":"Timothy Coughlin","role_category":"director","title":"Director","committee":"Audit · Chair","is_board_chair":false,"is_independent":true,"start_date":"2025-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"tyrell-j-rivers","display_name":"Tyrell J. Rivers","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2018-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"victor-sandor","display_name":"Victor Sandor","role_category":"director","title":"Director","committee":"Compensation","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null},{"person_slug":"viviane-monges","display_name":"Viviane Monges","role_category":"director","title":"Director","committee":"Audit; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null,"verification_status":"confirmed","confidence":0.85,"evidence":{"document_title":"ADC Therapeutics SA DEF 14A 2026-04-20","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2026-04-20","last_checked_at":"2026-04-24T15:46:02.182+00:00"},"headshot_url":null}],"executives":[],"coverage":{"schema_version":"alpha-leadership-coverage-v1","board_roster_scope":"def_14a_current_directors","executive_roster_scope":"NOT_ASSERTED","neo_set_status":"NOT_ASSERTED","board_roster_complete":false,"neo_set_complete":false,"notes":["Empty executives is NOT_ASSERTED, not a complete named-executive-officer set.","Form 4 occupancy is not a DEF 14A board.","Unconfirmed current sec_proxy DEF 14A directors may project. Confirmed is not required.","Unconfirmed current executives with first-party issuer evidence (source_url + effective date) may project.","Company-page directors do not require people.public_profile_enabled.","Completeness compares the latest first-party roster with the public projection; a source older than 180 days is STALE.","Do not remap HONA to HON 0000773840. Do not merge XOM 0000034088 with 0002115436.","Person match is projection-only. Name-only Person merges are forbidden."],"completeness":{"reasons":["NO_LEADERSHIP_SOURCE"],"board_completeness":"NOT_REVIEWED","completeness_schema":"alpha-leadership-completeness-v1","executive_team_completeness":"NOT_REVIEWED"},"parser_bleed_excluded":true,"former_titles_excluded":true,"identity_merge_forbidden":true,"form4_occupancy_is_not_board":true}},"governance":{"summary":"Current confirmed board seats plus verified executive Claims. Committees appear only when membership is stored on a current role.","boundary":"Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. Empty executives is NOT_ASSERTED, not a complete NEO set. Form 4 occupancy is not a DEF 14A board. Chair is never inferred from list order. Person identities are not merged on name.","committees":[{"name":"Audit","canonical_type":"audit","chair":"Timothy Coughlin","members":[{"display_name":"Timothy Coughlin","person_slug":"timothy-coughlin","is_chair":true,"committee_role":"chair"},{"display_name":"Robert Azelby","person_slug":"robert-azelby","is_chair":false,"committee_role":"member"},{"display_name":"Viviane Monges","person_slug":"viviane-monges","is_chair":false,"committee_role":"member"}],"source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":null,"source_id":"board_seats","note":"Projected from current board_seats committee assignments and chair flags. A combined environment, health, safety, and technology name uses the esg and technology flags. Chair is not inferred from list order. Person identities are not merged on name."},{"name":"Compensation","canonical_type":"compensation","chair":"Peter Hug","members":[{"display_name":"Peter Hug","person_slug":"peter-hug","is_chair":true,"committee_role":"chair"},{"display_name":"Robert Azelby","person_slug":"robert-azelby","is_chair":false,"committee_role":"member"},{"display_name":"Victor Sandor","person_slug":"victor-sandor","is_chair":false,"committee_role":"member"}],"source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":null,"source_id":"board_seats","note":"Projected from current board_seats committee assignments and chair flags. A combined environment, health, safety, and technology name uses the esg and technology flags. Chair is not inferred from list order. Person identities are not merged on name."},{"name":"Nominating and Governance","canonical_type":"nominating_governance","chair":"Jean-Pierre Bizzari","members":[{"display_name":"Jean-Pierre Bizzari","person_slug":"jean-pierre-bizzari","is_chair":true,"committee_role":"chair"},{"display_name":"Peter Hug","person_slug":"peter-hug","is_chair":false,"committee_role":"member"},{"display_name":"Viviane Monges","person_slug":"viviane-monges","is_chair":false,"committee_role":"member"}],"source_url":"https://www.sec.gov/Archives/edgar/data/1771910/000114036126015491/ny20070055x2_def14a.htm","source_type":null,"source_id":"board_seats","note":"Projected from current board_seats committee assignments and chair flags. A combined environment, health, safety, and technology name uses the esg and technology flags. Chair is not inferred from list order. Person identities are not merged on name."}],"disclosures":[{"record":"Audit","status":"Extracted","authority":"Issuer proxy / committee disclosure"},{"record":"Compensation","status":"Extracted","authority":"Issuer proxy / committee disclosure"},{"record":"Nominating and Governance","status":"Extracted","authority":"Issuer proxy / committee disclosure"}]},"permissions":{"classification":"open_public_projection","public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false},"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"structured_data":{"@context":["https://schema.org",{"alpha":"https://alpha.ac/ns/","indexMembership":"alpha:indexMembership","indexProvider":"alpha:indexProvider","indexMembershipStatus":"alpha:indexMembershipStatus","indexEffectiveDate":"alpha:indexEffectiveDate","indexAnnouncementDate":"alpha:indexAnnouncementDate","indexRemovalDate":"alpha:indexRemovalDate","lastVerifiedAt":"alpha:lastVerifiedAt","verificationStatus":"alpha:verificationStatus","evidence":"alpha:evidence"}],"@type":"ProfilePage","@id":"https://registry.alpha.ac/companies/adc-therapeutics-sa#profile","url":"https://registry.alpha.ac/companies/adc-therapeutics-sa","dateModified":"2026-10-17T04:46:43.578776+00:00","mainEntity":{"@type":"Organization","@id":"https://registry.alpha.ac/companies/adc-therapeutics-sa#organization","legalName":"ADC Therapeutics SA","name":"ADC Therapeutics SA","description":"ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients ","url":"https://registry.alpha.ac/companies/adc-therapeutics-sa","addressCountry":"US","indexMembership":[],"member":[{"@type":"OrganizationRole","roleName":"Director","startDate":"2022-01-01","member":{"@type":"Person","name":"Ameet Mallik","url":"https://registry.alpha.ac/people/ameet-mallik"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2022-01-01","member":{"@type":"Person","name":"Jean-Pierre Bizzari","url":"https://registry.alpha.ac/people/jean-pierre-bizzari"}},{"@type":"OrganizationRole","roleName":"Director","member":{"@type":"Person","name":"Jose Pepe Carmona","url":"https://registry.alpha.ac/people/jose-pepe-carmona"}},{"@type":"OrganizationRole","roleName":"Director","member":{"@type":"Person","name":"Mohamed Zaki","url":"https://registry.alpha.ac/people/mohamed-zaki"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2019-01-01","member":{"@type":"Person","name":"Peter Hug","url":"https://registry.alpha.ac/people/peter-hug"}},{"@type":"OrganizationRole","roleName":"Director","member":{"@type":"Person","name":"Peter J. Graham","url":"https://registry.alpha.ac/people/peter-j-graham"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Robert Azelby","url":"https://registry.alpha.ac/people/robert-azelby"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2020-01-01","member":{"@type":"Person","name":"Ron Squarer","url":"https://registry.alpha.ac/people/ron-squarer"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2025-01-01","member":{"@type":"Person","name":"Timothy Coughlin","url":"https://registry.alpha.ac/people/timothy-coughlin"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2018-01-01","member":{"@type":"Person","name":"Tyrell J. Rivers","url":"https://registry.alpha.ac/people/tyrell-j-rivers"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2020-01-01","member":{"@type":"Person","name":"Victor Sandor","url":"https://registry.alpha.ac/people/victor-sandor"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2021-01-01","member":{"@type":"Person","name":"Viviane Monges","url":"https://registry.alpha.ac/people/viviane-monges"}}]},"mainEntityOfPage":"https://registry.alpha.ac/companies/adc-therapeutics-sa"},"financials":{"kind":"financials","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"ownership":{"kind":"ownership","records":[],"limitation":"Only evidence-backed canonical_assertions already stored for this company. Empty records mean none are stored. Missing values are never invented. 13F and N-PX are not beneficial ownership and are never projected here.","source_table":"canonical_assertions","source_evidence_table":"canonical_source_records"},"registry_intelligence":{"schema_version":"alpha-registry-intelligence-v1","record_version":"d751713988987e9331980363e24189ce","subject":"alpha:company:adc-therapeutics-sa","as_of":"2026-10-17T10:23:17.924653+00:00","recorded_at":"2026-10-17T10:23:17.924653+00:00","availability":"available","records":[],"next_offset":null,"limitations":["Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage."]},"risk_oversight":{"schema_version":"alpha-risk-oversight-v1","subject":"alpha:company:adc-therapeutics-sa","record_version":"d751713988987e9331980363e24189ce","as_of":"2026-10-17T10:23:17.673388+00:00","recorded_at":"2026-10-17T10:23:17.673388+00:00","availability":"available","complete":true,"records":[],"limitations":["Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording.","An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence."]}},"canonical_source":"aegis_canonical","registry_intelligence":{"schema_version":"alpha-registry-intelligence-v1","record_version":"d751713988987e9331980363e24189ce","subject":"alpha:company:adc-therapeutics-sa","as_of":"2026-10-17T10:23:17.924653+00:00","recorded_at":"2026-10-17T10:23:17.924653+00:00","availability":"available","records":[],"next_offset":null,"limitations":["Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage."]},"risk_oversight":{"schema_version":"alpha-risk-oversight-v1","subject":"alpha:company:adc-therapeutics-sa","record_version":"d751713988987e9331980363e24189ce","as_of":"2026-10-17T10:23:17.673388+00:00","recorded_at":"2026-10-17T10:23:17.673388+00:00","availability":"available","complete":true,"records":[],"limitations":["Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording.","An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence."]}}